BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB

Provided By PR Newswire

Last update: Jul 17, 2025

NEW YORK, July 17, 2025 BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification from The Nasdaq Stock Market LLC, informing the company that its common stock will be delisted from the Nasdaq Capital Market. Trading of BrainStorm's common stock on Nasdaq will be suspended at the open of trading on July 18, 2025.